 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ORGCAR19 / Orgenesis
Trial completion: OREA: Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris (clinicaltrials.gov) - Jan 24, 2024
P1, N=38, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed
- | ORGCAR19 / Orgenesis
Trial completion date, Trial primary completion date: OREA: Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris (clinicaltrials.gov) - Nov 26, 2023
P1, N=38, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
- || ORGCAR19 / Orgenesis
Enrollment change, Trial completion date, Trial primary completion date: OREA: Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris (clinicaltrials.gov) - Jul 12, 2022
P1, N=38, Recruiting, Sponsor: Origimm Biotechnology GmbH
Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023 N=60 --> 38 | Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: Feb 2023 --> Jun 2023
- ||| ORGCAR19 / Orgenesis
New P1 trial: OREA: Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris (clinicaltrials.gov) - Nov 22, 2021
P1, N=60, Recruiting, Sponsor: Origimm Biotechnology GmbH